Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved ...

Pfizer acquired the Eucrisa (crisaborole) when it bought its developer, Anacor in May this year for $5.2 billion. Skip to main content Monday 17 June 2024 ...

Researchers in the Department of Dermatology are seeking participants age 2-17 with eczema for a research study. This study is investigating whether crisaborole (Eucrisa) can reduce topical steroid ...

In December, Eucrisa became the first PDE-4 blocker approved to treat mild-to-moderate eczema for people ages 2 and older. Pfizer declined to comment on the campaign.

Your eczema (atopic dermatitis) may be a part of you, but it doesn’t have to define you. Living with eczema might take some effort, like changing your lifestyle and working with your physicia… ...

Atopic dermatitis, also known as eczema, is a skin condition that may affect people of all races and ethnicities, but may occur more frequently in African-American children.[1] According to US ...

With the winter months comes colder, drier air, which can impact those prone to atopic dermatitis (AD), also known as eczema.1,2 But for the nearly 18 million children and adults in the U.S. living… ...

Your eczema (atopic dermatitis) may be a part of you, but it doesn’t have to define you. Living with eczema might take some effort, like changing your lifestyle and working with your physicia… ...